DOCS · Healthcare & Life Sciences · US GAAP

Doximity

Doximity earnings analysis for investors, students, and job seekers. We connect the customer situation and competitive choices to revenue, operating profit, the balance sheet, and cash generation.

Revenue
$645M
Operating profit
$215M
Operating margin
33.3%
Revenue growth
+13.2%

Growth only matters when the economics hold.

FY2022$344M
FY2023$419M
FY2024$475M
FY2025$570M
FY2026$645M

Why customers choose this business

when patients and professionals need better outcomes with less risk, pain, delay, or uncertainty. The underlying human motives are survival, safety, dignity, autonomy, and hope. That is the demand context behind the reported numbers—not a separate “marketing” discussion.

For Doximity, the practical question is whether management is making that situation easier, more reliable, or more rewarding than the alternatives. The benefit competitors include standard of care, generics, alternative therapies, watchful waiting, prevention, and non-treatment.

How customer behavior becomes financial performance

The core mechanism is turning clinical evidence, access, adherence, and professional trust into treated patients and durable economics. If it works, customer behavior first moves operating indicators, then revenue and gross economics, and finally operating profit and cash flow. If it fails, the same investment can appear as higher acquisition cost, inventory, depreciation, or working-capital pressure.

whether research, capacity, and access investment expands treated demand before patent, reimbursement, or safety risk erodes value.

All reports for Doximity

Compare companies serving a similar need

TikTokで見る